Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Hoare, Alexander ^a   Kerr, Stephen J ^a,b   Ruxrungtham, Kiat ^b,c   Ananworanich, Jintanat ^a,b,c   Law, Matthew G ^a   Cooper, David A ^a   Phanuphak, Praphan ^b,c   Wilson, David P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EPIDEMIC; HEALTH CARE ACCESS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; SOUTHEAST ASIA; TREATMENT PLANNING; VIRUS LOAD; VIRUS STRAIN; VIRUS TRANSMISSION; DRUG EFFECT; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

ANTI-HIV AGENTS; ASIA, SOUTHEASTERN; DRUG RESISTANCE, VIRAL; HEALTH SERVICES ACCESSIBILITY; HIV; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 77956200568     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010981     Document Type: Article

References (58)

1. Rojanapithayakorn W (2006) The 100% Condom Use Programme in Asia. Reproductive Health Matters 14: 41-52.
2. (2009) Annual Repot 2008. NCHADS.
3. UNAIDS (2008) 2008 Report on the global AIDS epidemic. Geneva: UNAIDS.
4. WHO (2003) Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach; Geneva World Health Organization; Available at http://www.who.int.
5. Chasombat S, McConnell MS, Siangphoe U, Yuktanont P, Jirawattanapisal T, et al. (2009) National Expansion of Antiretroviral Treatment in Thailand, 2000-2007: Program Scale-Up and Patient Outcomes. J Acquir Immune Defic Syndr 50: 506-512.
6. Yam WC, Chen JH, Wong KH, Chan K, Cheng VC, et al. (2006) Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong. J Clin Virol 35: 454-457.
7. Gatanaga H, Ibe S, Matsuda M, Yoshida S, Asagi T, et al. (2007) Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 75: 75-82.
8. Chang SY, Chen MY, Lee CN, Sun HY, Ko W, et al. (2008) Trends of antiretroviral drug resistance in treatment-naive patients with human immunodeficiency virus type 1 infection in Taiwan. J Antimicrob Chemother 61: 689-693.
9. Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, Thongprapai H, Kittihanukul C, et al. (2008) Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. HIV Med 9: 322-325.
10. Srasuebkul P, Calmy A, Zhou J, Kumarasamy N, Law M, et al. (2007) Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). AIDS Res Ther 4: 18.
11. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, et al. (1999) Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 37: 2291-2296.
12. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5: e158.
13. Peuchant O, Thiebaut R, Capdepont S, Lavignolle-Aurillac V, Neau D, et al. (2008) Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 22: 1417-1423.
14. Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, Suebsaeng L, Lo YR (2006) The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand. Southeast Asian J Trop Med Public Health 37: 704-715.
15. Bunjumnong O. Thailand: access to antiretroviral treatment under Universal Health Care Scheme; 2002; Barcelona.
16. Maneesriwongul WL, Tulathong S, Fennie KP, Williams AB. (2006) Adherence to antiretroviral medication among HIV-positive patients in Thailand. J Acquir Immune Defic Syndr 43(Suppl 1): S119-122.
17. Wilson DP, Kahn J, Blower SM (2006) Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide. Proc Natl Acad Sci U S A 103: 14228-14233.
18. Blower S, Bodine E, Kahn J, McFarland W (2005) The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 19: 1-14.
19. Blower S, Ma L, Farmer P, Koenig S (2003) Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord 3: 345-353.
20. Sanchez MS, Grant RM, Porco TC, Gross KL, Getz WM (2005) A decrease in drug resistance levels of the HIV epidemic can be bad news. Bull Math Biol 67: 761-782.
21. Brown T, Peerapatanapokin W. (2004) The Asian Epidemic Model: a process model for exploring HIV policy and programme alternatives in Asia. Sex Transm Infect 80: Suppl 1 i19-24.
22. Ruxrungtham K, Brown T, Phanuphak P (2004) HIV/AIDS in Asia. Lancet 364: 69-82.
23. Weniger BG, Limpakarnjanarat K, Ungchusak K, Thanprasertsuk S, Choopanya K, et al. (1991) The epidemiology of HIV infection and AIDS in Thailand. AIDS 5: Suppl 2 S71-85.
24. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929.
25. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM (2008) Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 372: 314-320.
26. King MS, Brun SC, Kempf DJ (2005) Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J Infect Dis 191: 2046-2052.
27. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, et al. (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×10(9) cells/L. Ann Intern Med 139: 810-816.
28. Tam LW, Chui CK, Brumme CJ, Bangsberg DR, Montaner JS, et al. (2008) The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr 49: 266-271.
29. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, et al. (2006) Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20: 223-231.
30. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, et al. (2004) Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis 190: 162-165.
31. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, et al. (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17: 1925-1932.
32. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, et al. (2005) Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191: 339-347.
33. Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, et al. (2007) Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials 8: 282-292.
34. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, et al. (2005) Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 19: 487-494.
35. Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, et al. (2007) Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 370: 1923-1928.
36. Blower SM, Dowlatabadi H (1994) Sensitivity and Uncertainty Analysis of Complex-Models of Disease Transmission: an HIV Model, as an Example. International Statistical Review 62: 229-243.
37. Hoare A, Regan DG, Wilson DP (2008) Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Theoretical Biology and Medical Modelling 5: 4.
38. Attia S, Egger M, Muller M, Zwahlen M, Low N (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397-1404.
39. Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, et al. (2008) Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 9: 883-896.
40. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, et al. (2006) Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 3: e356.
41. Larder BA, Darby G, Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
42. Ho DD, Moudgil T, Alam M (1989) Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 321: 1621-1625.
43. Choi JY, Kim EJ, Park YK, Lee JS, Kim SS (2008) National survey for drug-resistant variants in newly diagnosed antiretroviral drug-naive patients with HIV/AIDS in South Korea: 1999-2005. J Acquir Immune Defic Syndr 49: 237-242.
44. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V (2009) Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 28: 826-830.
45. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, et al. (2006) High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic Ill) 5: 152-156.
46. Booth CL, Geretti AM (2007) Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056.
47. Tang JW, Pillay D (2004) Transmission of HIV-1 drug resistance. J Clin Virol 30: 1-10.
48. Van Laethem K, De Munter P, Schrooten Y, Verbesselt R, Van Ranst M, et al. (2007) No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol 39: 43-47.
49. Cohen GM (2007) Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries. AIDS 21: Suppl 4 S81-87.
50. WHO (2008) Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector.
51. Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, et al. (2009) High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 49: 306-309.
52. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, et al. (2005) The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 38: 174-179.
53. Sirivichayakul S, Phanuphak P, Pankam T, R OC, Sutherland D, et al. (2008) HIV drug resistance transmission threshold survey in Bangkok, Thailand. Antivir Ther 13: Suppl 2109-113.
54. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, et al. (2007) Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 44: 447-452.
55. (2009) Rapid advice Antiretroviral therapy for HIV infection in adults and adolescents. Geneva: The World Health Organisation.
56. (2009) Meeting report: revision of WHO ART guidelines for adults and adolescents. Geneva: The World Heath Organisation.
57. Sungkanuparph S, Techasathi W, Teeraratkul A, Chasombat S, Bhakeecheepe S, et al. (2010) Thai National Guidelines for Antiretroviral Therapy in HIV-1 Infected Adults and Adolescents 2010. Asian Biomedicine (in press).
58. Apisarnthanarak A, Mundy LM (2008) Antiretroviral drug resistance among antiretroviral-naive individuals with HIV infection of unknown duration in Thailand. Clin Infect Dis 46: 1630-1631.